Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774144 | 0.88 | KMT2A (0.34) | RIPK1KMT2AMTNR1AMYC | |
| SCHEMBL4887310 | 0.85 | ADRA2A (0.37) | RIPK1KMT2AMTNR1A | |
| SCHEMBL4897077 | 0.83 | RIPK1 (0.38) | RIPK1KMT2ASRCMYC | |
| SCHEMBL4895013 | 0.82 | CRHR1 (0.39) | RIPK1KMT2A | |
| SCHEMBL4897407 | 0.81 | CYP1A2 (0.39) | RIPK1KMT2A | |
| SCHEMBL4895917 | 0.76 | GSK3B (0.37) | — | |
| Hydrochloric Acid SCHEMBL21496574 | 0.74 | RIPK1 (0.43) | RIPK1 | |
| Hydrochloric Acid SCHEMBL21496575 | 0.74 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL4896701 | 0.72 | AADAT (0.43) | RIPK1 | |
| SCHEMBL2282815 | 0.72 | SCN9A (0.43) | RIPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | RIPK1 3999/4885KMT2A 911/4885MTNR1A 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.